<DOC>
	<DOC>NCT01970072</DOC>
	<brief_summary>The purpose of this study is to evaluate and compare the Pharmacokinetics/Pharmacodynamics and safety of Remimazolam Tosylate with midazolam in healthy volunteers</brief_summary>
	<brief_title>A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy males or females Weight range 50 to 100 kg inclusive Body mass index (BMI) 18 to 26 kg/m2 Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are contraindicated With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor Has known or suspected history of alcoholism or drug abuse or misuse within 6 months of Screening or evidence of tolerance or physical dependence before dosing with study drug With a history of laboratory results that show the presence of hepatitis B surface antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV) Pregnant,lactating Mallampati score ≥3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Remimazolam Tosylate</keyword>
	<keyword>Phase Ⅰ study</keyword>
	<keyword>Health</keyword>
</DOC>